Non-Alcoholic Fatty Liver Disease (NAFLD), a burgeoning health concern, is often underdiagnosed due to its subtle presentation.
NAFLD, associated with obesity and metabolic syndrome, is becoming prevalent worldwide. Its progression to Non-Alcoholic Steatohepatitis (NASH) can lead to cirrhosis, hepatocellular carcinoma, and liver failure.
Management of NAFLD involves lifestyle changes, weight loss, and control of associated conditions. Pharmacological interventions are limited but evolving. Early detection through regular screening is crucial.
Unmasking NAFLD is integral for preventing its catastrophic outcomes. A multidisciplinary approach including dietary and lifestyle modifications, along with pharmacotherapy, is essential for effective management. The role of healthcare professionals is pivotal in early detection and intervention.
1.
Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?
2.
Inconclusive BRCA Results Linked to Higher BC Risk
3.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
4.
PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.
5.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
1.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
2.
Critical Care Challenges in Oncologic Emergencies
3.
AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence
4.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
5.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
From Guidelines to Practice: Hematology
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation